Radiopharm Theranostics has reported encouraging interim results from its ongoing Phase 2b clinical trial of RAD 101, an experimental imaging agent designed to improve the detection of recurrent brain metastases.
Radiopharm reports strong interim results for brain metastases imaging agent
March 24, 2026 Australian Biotech
Latest Video
New Stories
-
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Bellberry announces new appointment to board of directors
July 27, 2026 - - Latest News -
The power of this commitment might be as a comparison of national intent
July 27, 2026 - - Latest News -
New AI platform aims to give patients a strong voice in medicines funding
July 27, 2026 - - Latest News

